Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

12.5%

2 terminated/withdrawn out of 16 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

25%

4 trials in Phase 3/4

Results Transparency

63%

5 of 8 completed trials have results

Key Signals

4 recruiting5 with results

Enrollment Performance

Analytics

Phase 1

5(41.7%)

Phase 3

3(25.0%)

Phase 2

2(16.7%)

Phase 4

1(8.3%)

N/A

1(8.3%)

12Total

Phase 1(5)

Phase 3(3)

Phase 2(2)

Phase 4(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials

NCT04756037Phase 3Active Not Recruiting

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy

Role: lead

NCT05739123Recruiting

Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring

Role: lead

NCT05329935Recruiting

Congenital Athymia Patient Registry

Role: lead

NCT05862272Phase 3Recruiting

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Role: lead

NCT05739136Active Not Recruiting

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

Role: lead

NCT06439524Phase 3Recruiting

The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial

Role: collaborator

NCT02274662Phase 4Completed

Expanded Access Protocol Thymus Transplantation

Role: lead

NCT01220531Not ApplicableCompleted

Thymus Transplantation Safety-Efficacy

Role: lead

NCT00579709Phase 1Completed

Thymus Transplantation With Immunosuppression